Michael Ackermann, CEO of start-up Oculeve, gives an update on his work with Allergan following the purchase of his company and its Dry Eye device. Ackermann explains how he’s fitting into Allergan’s folds and when we might expect to see Oculeve’s neurostimulation device.
Michael Ackermann, PhD
Michael is currently Vice President, Neurostimulation for Allergan, plc, and most recently CEO of Oculeve, Inc., which was acquired by Allergan in August 2015. He has eleven years of experience in medical technology development in both academic and industrial settings in the fields of ophthalmology, chronic pain and movement disorders.